Suppr超能文献

阿替利珠单抗联合贝伐珠单抗化疗治疗主门静脉主干癌栓肝癌的完全病理缓解。

Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk.

机构信息

Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Department of Pathology, Nagasaki University Hospital, Nagasaki, Japan.

出版信息

Dig Surg. 2023;40(1-2):84-89. doi: 10.1159/000529405. Epub 2023 Feb 27.

Abstract

We report a case of pathologic complete response after successful treatment for advanced hepatocellular carcinoma (HCC) complicated with portal venous tumor thrombus with atezolizumab and bevacizumab followed by radical resection. The patient was a male in his 60s. During follow-up for chronic hepatitis B, abdominal ultrasonography revealed a huge tumor located in the right lobe of the liver with the portal vein thrombosed by the tumor. The tumor thrombus extended to the proximal side of the left branch of the portal vein. The patient's tumor marker levels were elevated (alpha-phetoprotein, 14,696 ng/mL; PIVKA-II, 2,141 mAU/mL). Liver biopsy revealed poorly differentiated HCC. The lesion was categorized as advanced stage according to the BCLC staging system. As systemic therapy, atezolizumab plus bevacizumab was administered. Imaging showed marked shrinkage of the tumor and portal venous thrombus with a remarkable decrease of tumor marker levels after 2 courses of chemotherapy. After 3 additional courses of chemotherapy, radical resection was considered possible. The patient underwent right hemihepatectomy and portal venous thrombectomy. A pathological examination revealed a complete response. In conclusion, we experienced a case in which advanced HCC was curatively treated with atezolizumab plus bevacizumab, which was administered as systemic therapy with a view to conversion surgery.

摘要

我们报告了一例成功治疗合并门静脉癌栓的晚期肝细胞癌(HCC)后出现病理完全缓解的病例,该患者接受了阿替利珠单抗和贝伐珠单抗治疗,随后进行了根治性切除术。患者为 60 多岁男性,因慢性乙型肝炎随访时,腹部超声检查发现肝脏右叶有一个巨大肿瘤,肿瘤血栓阻塞门静脉。肿瘤血栓延伸至门静脉左支近端。患者的肿瘤标志物水平升高(甲胎蛋白,14696ng/ml;异常凝血酶原,2141mAU/ml)。肝活检显示低分化 HCC。根据巴塞罗那临床肝癌分期系统,病变被归类为晚期。作为系统治疗,给予阿替利珠单抗联合贝伐珠单抗治疗。化疗 2 个疗程后,影像学显示肿瘤和门静脉血栓明显缩小,肿瘤标志物水平显著下降。在另外 3 个疗程化疗后,认为可以进行根治性切除术。患者接受了右半肝切除术和门静脉血栓切除术。病理检查显示完全缓解。总之,我们治疗了一例晚期 HCC,使用阿替利珠单抗联合贝伐珠单抗进行全身治疗,以期进行转化手术。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验